International Journal of Clinical Oncology最新文献

{"title":"Serum albumin is associated with immune-related hypothyroidism and treatment continuity in non-small cell lung cancer.","authors":"Kenji Takada, Maki Tanioka, Yoshito Zamami, Shinichi Toyooka, Yoshinobu Maeda","doi":"10.1007/s10147-026-03202-z","DOIUrl":"https://doi.org/10.1007/s10147-026-03202-z","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) are a standard treatment for advanced non-small cell lung cancer (NSCLC), but clinically practical predictors of immune-related adverse events (irAEs) and treatment continuity remain limited.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using two nationwide Japanese administrative claims databases: Medical Data Vision (MDV) and the Japan Medical Data Center (JMDC). Patients with advanced NSCLC treated with ICIs were identified. Those with available thyroid function data were included in analyses of ICI-induced hypothyroidism (MDV, n = 1786; JMDC, n = 1083), and patients receiving first-line ICIs were analyzed for treatment continuity (MDV, n = 1088; JMDC, n = 1007). Machine learning models including Elastic Net were developed and externally validated to predict hypothyroidism. Treatment durability was assessed using time to next treatment or death (TTNT-D).</p><p><strong>Results: </strong>Elastic Net showed the most consistent performance across cohorts (AUC: 0.72 training, 0.73 validation, 0.71 test). Baseline thyroid-stimulating hormone (TSH) was the strongest predictor of hypothyroidism. Serum albumin consistently emerged as an important predictor across all machine learning models. Higher albumin levels were associated with an increased incidence of hypothyroidism and significantly prolonged TTNT-D (MDV: HR 0.75; JMDC: HR 0.79; both p  < 0.05). Patients with albumin ≥ 3.5 g/dL had markedly longer median TTNT-D compared with those < 3.0 g/dL (MDV: 15.3 vs 6.1 months; JMDC: 14.8 vs 5.4 months; both p  < 0.001).</p><p><strong>Conclusions: </strong>Baseline TSH was the strongest predictor of hypothyroidism, while serum albumin was associated with both hypothyroidism and treatment continuity in patients receiving first-line ICI therapy for NSCLC, suggesting its potential as a practical biomarker for clinical risk stratification.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057).","authors":"Kohei Kushiro, Yoko Tsukita, Takehiro Tozuka, Shinobu Hosokawa, Toshiyuki Sumi, Mao Uematsu, Osamu Honjo, Ou Yamaguchi, Hiroyuki Kyoyama, Kyoji Tsurumi, Yohei Suzuki, Daisuke Ishikawa, Naruo Yoshimura, Naoko Matsumoto, Hiromi Nagashima, Ryotaro Kida, Hiroshi Yokouchi, Minehiko Inomata, Nobuhiro Kanaji, Taichi Takashina, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina","doi":"10.1007/s10147-026-03206-9","DOIUrl":"https://doi.org/10.1007/s10147-026-03206-9","url":null,"abstract":"<p><strong>Background: </strong>Optimal management of older patients with advanced non-small cell lung cancer (NSCLC) following progression on immune checkpoint inhibitors (ICIs) remains uncertain, as large-scale evidence guiding second-line therapy in this population is limited. Thus, we performed this study to evaluate transition rates and clinical outcomes of subsequent treatments in older patients with NSCLC after first-line ICI-based therapy.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study included 1245 patients aged ≥ 75 years with advanced or recurrent epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangements-negative NSCLC who received first-line systemic therapy between December 2018 and March 2021 at 58 institutions in Japan. Outcomes included transition rates to second- and third-line therapy, progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).</p><p><strong>Results: </strong>Of all patients, 354 received ICI plus chemotherapy and 425 received ICI monotherapy. Disease progression occurred in 82% and 77% of patients, respectively. Second-line therapy (most commonly single-agent chemotherapy) was administered to 48% and 31%, respectively. Median PFS with single-agent chemotherapy was 3.7 months in both groups. Median OS was 9.5 and 9.9 months, respectively. ORRs were 11% and 13%, respectively. After progression, 35% and 32% of patients received third-line treatment, which demonstrated limited efficacy. In older patients with advanced NSCLC, transition to second-line therapy after first-line ICI-based treatment was limited. However, the efficacy of single-agent chemotherapy as second-line treatment was comparable to real-world outcomes reported prior to ICIs.</p><p><strong>Conclusions: </strong>These findings underscore the importance of providing appropriate second-line treatment for older patients. REGISTRY AND REGISTRATION NO.</p><p><strong>Of the study/trial: </strong>UMIN Clinical Trials Registry (UMIN000046700).</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma.","authors":"Noriomi Matsumura","doi":"10.1007/s10147-026-03211-y","DOIUrl":"https://doi.org/10.1007/s10147-026-03211-y","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial and documentation-related workload impact of ERAS implementation in major head and neck surgery with free flap reconstruction under the Japanese DPC system.","authors":"Kohtaro Eguchi, Go Omura, Azusa Sakai, Toshihiko Sakai, Chihiro Fushimi, Takayuki Imai, Takeshi Shinozaki, Masami Mukai, Kazuto Matsuura, Seiichi Yoshimoto","doi":"10.1007/s10147-026-03146-4","DOIUrl":"10.1007/s10147-026-03146-4","url":null,"abstract":"<p><strong>Background: </strong>Enhanced recovery after surgery (ERAS) improves postoperative recovery in head and neck oncologic surgery. However, its institutional impact under the Japanese Diagnosis Procedure Combination (DPC) system, particularly regarding hospital revenue and frontline workload, remains unclear.</p><p><strong>Methods: </strong>This retrospective cohort study included patients who underwent major resection of malignant head and neck tumors with free tissue transfer reconstruction at the National Cancer Center Hospital between April 2018 and March 2022. Patients were classified into pre-ERAS and post-ERAS groups according to implementation of the PreSte ERAS protocol in May 2020. Financial outcomes included DPC revenue, fee-for-service revenue, total hospital revenue, and revenue efficiency defined as revenue per hospital day. Frontline workload was assessed using the total number of characters documented in electronic medical records by non-physician healthcare professionals.</p><p><strong>Results: </strong>A total of 310 patients were analyzed (155 per group). Median length of stay decreased after ERAS implementation (25 vs. 23 days; p = 0.002). Total revenue showed a non-significant decreasing trend after ERAS implementation (109,360 vs. 98,626 points; p = 0.104). Revenue efficiency increased after ERAS implementation (3627 vs. 3984 points per hospital day; p < 0.001). Documentation volume tended to increase but did not differ significantly overall. Sensitivity analysis excluding free fibula flap reconstruction showed consistent results.</p><p><strong>Conclusion: </strong>ERAS implementation was associated with shorter hospitalization and improved revenue efficiency under the Japanese DPC-based system. Although total revenue did not increase, and an increased multidisciplinary workload cannot be excluded, these findings support the potential institutional feasibility of ERAS.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2322-2330"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study.","authors":"Kota Ishioka, Naomi Hayashi, Naoki Miyazaki, Akito Dobashi, Eri Habano, Asami Kuga, Keika Kaneko, Hiromi Arakawa, Yuko Minoura, Ippei Fukada, Masumi Yamazaki, Naoki Fukuda, Akemi Kataoka, Toshimi Takano, Masayuki Watanabe, Shunji Takahashi, Arisa Ueki, Makiko Ono","doi":"10.1007/s10147-026-03155-3","DOIUrl":"10.1007/s10147-026-03155-3","url":null,"abstract":"<p><strong>Background: </strong>Adolescents and young adults (AYA) aged 15 to 39 years with cancer have a higher prevalence of germline pathogenic variants than older patients. This study characterized the prevalence and distribution of germline pathogenic/likely pathogenic variants (GPVs) in Japanese AYA with advanced solid tumors using nationwide real-world paired tumor and normal sequencing data.</p><p><strong>Methods: </strong>This retrospective study was conducted using a nationwide cancer genomics database in Japan. In total, 359 AYA with solid tumors who underwent comprehensive genomic profiling with a paired tumor and normal samples between June 2019 and December 2023 were included. The analyses were restricted to 39 genes for which germline findings, defined as variants detected in the matched normal sample within genes eligible for germline disclosure in Japan, are clinically reportable.</p><p><strong>Results: </strong>Among 359 patients with advanced solid tumors, GPVs were identified in 32 patients, corresponding to a prevalence of 8.9%. Variants in the TP53 and BRCA2 genes were the most frequently identified. Notably, 13 of 32 cases were identified in an off-tumor context. In lung cancer, GPVs were identified in TP53 and BRCA2, indicating that GPVs in established cancer-predisposition genes can also be detected in tumor types not classically associated with these hereditary cancer genes. In univariable analysis, a family history of cancer and double cancer were associated with GPV positivity.</p><p><strong>Conclusions: </strong>This national paired tumor and normal sequencing study in Japanese AYA with cancer, identified GPVs including those detected in off-tumor contexts. Germline findings may warrant consideration beyond conventional approaches based on tumor type.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2460-2469"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study.","authors":"Takayuki Imai, Kohtaro Eguchi, Takeshi Shinozaki, Seiichi Yoshimoto, Sadamoto Zenda, Takuhiro Yamaguchi, Shunsuke Oyamada, Tomoka Okano, Tomoe Mashiko, Miyuki Kurosaki, Kenya Kobayashi, Tsuyoshi Harada, Yukinori Asada, Hiromichi Matsuoka, Kazuto Matsuura","doi":"10.1007/s10147-026-03138-4","DOIUrl":"10.1007/s10147-026-03138-4","url":null,"abstract":"<p><strong>Background: </strong>Enhanced Recovery After Surgery programs have been adopted for head and neck cancer surgery with free tissue transfer reconstruction, but postoperative recovery remains difficult because of the high invasiveness of this procedure. Corticosteroids administered before surgery reduce pain, nausea, and systemic inflammation in other surgical settings, but their benefit in this context is uncertain.</p><p><strong>Methods: </strong>This phase III, multicenter, randomized, double-blind, placebo-controlled trial was conducted at three tertiary cancer centers in Japan. A total of 180 adults undergoing head and neck cancer surgery with free tissue transfer reconstruction were randomly assigned to receive a single intravenous dose of 8 mg dexamethasone phosphate or placebo before surgery. The primary outcome was postoperative quality of recovery, assessed by total scores on the Japanese version of the Quality of Recovery questionnaire on postoperative days 2 and 4. Secondary outcomes included postoperative pain, nausea, systemic inflammatory markers, postoperative complications, and length of hospital stay.</p><p><strong>Results: </strong>Among 178 evaluable patients, postoperative quality of recovery did not differ significantly between the dexamethasone and placebo groups. No significant differences were observed in postoperative pain or nausea. Dexamethasone significantly reduced postoperative serum interleukin-6 and C-reactive protein levels but did not improve patient-reported recovery or shorten hospitalization. Overall postoperative complication rates were similar between the groups.</p><p><strong>Conclusions: </strong>Preoperative dexamethasone reduced systemic inflammation but did not improve postoperative recovery, pain, or nausea after head and neck cancer surgery with free tissue transfer reconstruction. Inflammation control alone may be insufficient to enhance recovery after highly invasive surgery.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2331-2341"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive peritoneal cytology and recurrence patterns in endometrial cancer according to postoperative recurrence risk classification: a retrospective cohort study.","authors":"Nozomi Yachida, Megumi Kurosawa, Kyota Saito, Hidehiko Akashi, Miho Suzuki, Risa Kudo, Ryo Tamura, Takahiro Minamikawa, Akiko Kobayashi, Sosuke Adachi, Koji Nishino, Kosuke Yoshihara","doi":"10.1007/s10147-026-03124-w","DOIUrl":"10.1007/s10147-026-03124-w","url":null,"abstract":"<p><strong>Purpose: </strong>The clinical significance of positive peritoneal cytology (PPC) in endometrial cancer remains controversial, particularly in low-risk disease. This study investigated the distribution of PPC across postoperative recurrence risk groups and its associations with clinicopathological features, recurrence patterns, menopausal status, and exploratory survival outcomes.</p><p><strong>Methods: </strong>We retrospectively analyzed 757 patients with endometrial cancer who underwent hysterectomy between 2002 and 2021. Clinicopathological characteristics, recurrence patterns, and exploratory survival outcomes were evaluated according to peritoneal cytology status within postoperative recurrence risk groups.</p><p><strong>Results: </strong>PPC was observed in 29.9% of patients, including 20.0% of the low-risk group. PPC was associated with adverse pathological features, including advanced stage, lymphovascular space invasion, deep myometrial invasion, cervical stromal invasion, and adnexal involvement. PPC was more frequent among premenopausal patients. However, among patients with PPC, menopausal status was not associated with progression-free survival (PFS) or overall survival (OS). PPC was associated with peritoneal recurrence in the overall cohort (9.3% vs. 1.9%, P < 0.001), with a trend in the low-risk group (P = 0.057). In exploratory multivariable analyses, PPC was associated with shorter PFS in the low-risk group (P = 0.009) but not with OS.</p><p><strong>Conclusion: </strong>PPC was observed across all postoperative recurrence risk groups, including low-risk disease, and was associated with adverse clinicopathological features and peritoneal recurrence. The higher frequency of PPC in premenopausal patients, despite no association between menopausal status and prognosis among cytology-positive patients, suggests heterogeneity in the mechanisms underlying cytological positivity. These findings are hypothesis-generating and require prospective validation.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2271-2281"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)-breast cancer.","authors":"Yuko Takano, Akihiko Shimomura, Sachi Morita, Taijiro Kosaka, Yumiko Koi, Emi Tokuda, Fumio Nagashima, Ayumu Matsuoka, Masataka Sawaki","doi":"10.1007/s10147-026-03173-1","DOIUrl":"10.1007/s10147-026-03173-1","url":null,"abstract":"<p><strong>Background: </strong>The number of older adults with early breast cancer is rising in aging societies. Optimal perioperative systemic therapy for this population remains challenging, owing to heterogeneity in functional status, comorbidities, and the limited representation of older patients in clinical trials.</p><p><strong>Methods: </strong>This article presents an English digest of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer (Second Edition), focusing on perioperative systematic therapy for early breast cancer. The guidelines were developed in accordance with the Minds 2020 methodology, incorporating systematic reviews, the Evidence-to-Decision framework, and multidisciplinary consensus.</p><p><strong>Results: </strong>The guidelines address key clinical questions regarding perioperative systemic therapy for older patients with breast cancer, including human epidermal growth factor receptor 2 (HER2)-targeted therapy, immune checkpoint inhibitors, and treatment intensification strategies for hormone receptor-positive disease. Most recommendations are conditional because of limited direct evidence in older populations. Trastuzumab-based therapy remains the standard approach for HER2-positive disease, whereas alternative strategies may be considered for patients who are unable to tolerate chemotherapy. Immune checkpoint inhibitors combined with chemotherapy may improve recurrence-related outcomes in selected patients; however, evidence in older populations is limited. Additional therapies, such as abemaciclib or S-1, may reduce the risk of recurrence in high-risk patients but require careful consideration of toxicity.</p><p><strong>Conclusions: </strong>These guidelines provide practical, evidence-based recommendations for perioperative systemic therapy in older adults with early breast cancer. They emphasize individualized treatment strategies that integrate patient characteristics, treatment goals, and tolerability. Further research specifically targeting older populations is needed to strengthen the evidence base for geriatric oncology.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2095-2101"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Workforce and institutional factors associated with comprehensive genomic profiling utilization in gynecologic oncology: a nationwide questionnaire survey in Japan.","authors":"Tamotsu Sudo, Kenta Masuda, Katsutoshi Oda, Hidemichi Watari, Akira Hirasawa, Shinya Sato, Kenichi Harano, Satoru Nagase, Kazuhiro Takehara, Masaki Mandai, Yuko Sasajima, Hirouki Yanai, Hitoshi Tsuda, Yusuke Kobayashi, Kei Kawana, Mikio Mikami, Kiyoko Kato, Daisuke Aoki, Aikou Okamoto","doi":"10.1007/s10147-026-03143-7","DOIUrl":"10.1007/s10147-026-03143-7","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive genomic profiling (CGP) has been widely introduced into precision oncology; however, its real-world implementation in gynecologic oncology remains unclear. This study evaluated nationwide CGP utilization, treatment translation, and management of secondary germline findings in Japanese gynecologic oncology.</p><p><strong>Methods: </strong>A nationwide survey was conducted across 98 institutions participating in gynecologic oncology training and/or Japan's cancer genomic medicine network. Institutional characteristics, workforce composition, treatment translation, and management of germline findings were assessed. Associations between institutional factors and CGP utilization or trial-related treatment translation were analyzed using incidence rate ratios (IRRs) with 95% confidence intervals.</p><p><strong>Results: </strong>Among 68 institutions with complete CGP volume data, 6,964 CGP tests were performed, including 922 for gynecologic malignancies. The median number of gynecologic CGP tests per institution was 10. In multivariate analysis, the number of board-certified obstetrician-gynecologists was associated with CGP utilization (IRR, 1.05; 95% CI 1.01-1.08). CGP-guided therapy was delivered to 80 patients (8.7%). Trial-related treatment translation was associated with the number of board-certified obstetrician-gynecologists (IRR, 1.09; 95% CI 1.02-1.16) and the presence of a medical oncology department (IRR, 7.93; 95% CI 1.41-44.72). Presumed germline pathogenic variants were identified in 100 cases (10.8%); however, confirmatory germline testing was performed in only 38 cases.</p><p><strong>Conclusion: </strong>CGP utilization in Japanese gynecologic oncology was associated with gynecologic workforce capacity and multidisciplinary genomic infrastructure. Collaboration between gynecologic oncology and medical oncology may facilitate treatment translation. CGP may also serve as an entry point for hereditary cancer evaluation despite incomplete downstream germline evaluation.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2405-2414"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.","authors":"Chika Nitani, Junichi Hara, Hiroshi Kawamoto, Tomoaki Taguchi, Yuki Yuza, Shuhei Karakawa, Kimikazu Matsumoto, Toshimi Kimura, Kenichi Yoshimura, Kiyoshi Yoshimura, Akinobu Hamada","doi":"10.1007/s10147-026-03142-8","DOIUrl":"10.1007/s10147-026-03142-8","url":null,"abstract":"<p><strong>Background: </strong>Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of a regimen containing granulocyte colony-stimulating factor (G-CSF)/teceleukin (regimen A) to that with GM-CSF/aldesleukin/isotretinoin (regimen B) in children with newly diagnosed high-risk neuroblastoma.</p><p><strong>Methods: </strong>After completing initial therapy including high-dose chemotherapy followed by autologous stem cell transplantation and radiotherapy, children with non-progressive disease were randomized to regimen A or B. Regimen B was identical to the immunotherapy regimen tested in ANBL0032 (six cycles of isotretinoin and five concomitant cycles of dinutuximab alternating with GM-CSF and aldesleukin). Regimen A consisted of six cycles of dinutuximab alternating with G-CSF and teceleukin. Event-free survival (EFS) and overall survival (OS) were compared between two regimens.</p><p><strong>Results: </strong>In total, 35 patients (16 receiving regimen A and 19 receiving regimen B) were enrolled. The 2-year EFS was 80.8% for patients receiving regimen A and 62.3% for those receiving regimen B, and their OS rates were 93.8% and 100.0%, respectively. The hazard ratio of regimen A compared to regimen B for EFS was 0.494 (upper limit of one-sided 70% confidence interval: 0.710), suggesting comparable efficacy of the two regimens. Frequently recorded grade 3/4 adverse events were fever, infection, and hematologic toxicity with no obvious difference in incidence between the regimens.</p><p><strong>Conclusions: </strong>Our results suggest that the efficacy of the alternative regimen containing G-CSF is comparable to that of the ANBL0032 regimen, providing a rationale for further evaluation in a phase III trial.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2382-2393"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}